X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Vantage Cancer Care Network Collaborates with Alliance Cancer Specialists, PC, to Expand the Delivery of High-Quality Cancer Care across Philadelphia

Content Team by Content Team
16th January 2018
in Research & Development
Vantage Cancer Care Network Collaborates with Alliance Cancer Specialists, PC, to Expand the Delivery of High-Quality Cancer Care across Philadelphia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Vantage Cancer Care Network (VCCN), a leader in value-based integrated cancer care, announced an agreement with Alliance Cancer Specialists, PC, to expand the delivery of high-quality oncology care across the Philadelphia region. Under the agreement, 21 oncologists across 11 locations are joining VCCN and will collaborate on providing seamless and efficient oncology care.

“We are privileged to join the Vantage Cancer Care Network in order to more closely align with like-minded physicians striving to improve quality and outcomes while lowering the overall cost of cancer care,” said Ann Marie Edwards, chief executive officer, Alliance Cancer Specialists, PC.

Physicians will benefit from VCCN’s expertise on value-based agreements, analytics tools, and process-improvement insights to help them achieve savings and quality outcomes in a value-based environment. As a result of this collaboration, VCCN will have a network of nearly 100 oncologists across 28 locations in the Philadelphia region.

“VCCN is pleased to join forces with Alliance Cancer Specialists,” said John Iacuone, MD, president & chief clinical officer, Vantage Cancer Care Network. “Alliance and VCCN are committed to working together so citizens of Philadelphia have access to high-quality cancer care and a superior patient experience, all while providing value to our health plan colleagues.”

About Alliance Cancer Specialists, PC
At Alliance, we’ve aligned the largest community-based team of cancer experts in Southeastern Pennsylvania. We offer quality cancer care that provides every advantage to help control and cure the disease.

Our approach guarantees new patients will be seen within 48 hours by one of our cancer experts. After evaluation, our team will provide a well-coordinated, tailored plan with diagnostic testing, the most powerful and precise treatment options, and compassionate care. With our combined strength and broad expertise, we provide the highest level of service to our patients and referring physicians in the Delaware Valley. To learn more visit www.alliancecancer.com

About Vantage Cancer Care Network
Vantage Cancer Care Network (VCCN) was founded to optimize cancer outcomes in a value-based, patient-centered care environment by developing cancer care networks to deliver appropriate, personalized and cost-effective care. VCCN is providing solutions to meet the growing needs of the oncology marketplace such as Carelytics™, a data management and reporting analytics tool. VCCN works with various oncology specialties to manage patient care through evidence-based treatment modalities. VCCN is supported by McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care.

PR Contact
Claire Crye, VCCN
Claire.Crye@McKesson.com

Tina Bellanca, Alliance Cancer Specialists, PC
TBellanca@lmiadvertising.com

Previous Post

START & Sarah Cannon Partner to Advance Therapies for Patients with Cancer

Next Post

iMedrix Announces General Availability of KardioScreen, a CE certified, Connected ECG Device for Universal Use

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post

iMedrix Announces General Availability of KardioScreen, a CE certified, Connected ECG Device for Universal Use

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In